InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones InflaRx (Nasdaq: IFRX) reported full‑year 2025 results and highlighted positive Phase 2a data for oral C5aR inhibitor izicopan, prioritizing hidradenitis suppurativa (HS) and discussing Phase 2b design with the FDA. Cash and marketable securities totaled €46.2 million, funding operations to mid‑2027.Company plans a China PK bridging study, ongoing collaborator discussions, and a virtual Capital Markets Day this spring.

#IFRX InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones

www.stocktitan.net/news/IFRX/infla-rx-repor...

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting InflaRx (Nasdaq: IFRX) announced a late-breaking oral presentation of Phase 3 vilobelimab results in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting in Denver, March 27-31, 2026.The oral session is scheduled for March 28, 2026, 2:24-2:36 PM MT, presenter Benjamin Kaffenberger, MD. The company also highlights its izicopan program and anti-C5a/C5aR platform.

#IFRX InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

www.stocktitan.net/news/IFRX/infla-rx-annou...

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference InflaRx (Nasdaq: IFRX) will participate in the Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026, with a fireside chat on March 9 at 9:20 AM ET and one-on-one investor meetings the same day.Live streaming and replay of the fireside chat will be available via a company link; investor relations contacts are provided for meeting requests.

#IFRX InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

www.stocktitan.net/news/IFRX/infla-rx-annou...

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals

#IFRX InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

www.stocktitan.net/news/IFRX/infla-rx-provi...

InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 InflaRx (Nasdaq: IFRX) announced the World Health Organization has granted the international nonproprietary name izicopan for its oral C5aR inhibitor formerly known as INF904; the name will be published in the WHO recommended INN list.Izicopan has shown tolerability in first‑in‑human single doses (3–240 mg) and multiple doses (30 mg once daily to 90 mg twice daily), pharmacokinetic/pharmacodynamic support with a ≥90% blockade of C5a‑induced neutrophil activation over 14 days, and topline Phase 2a signals of clinical activity in hidradenitis suppurativa and chronic spontaneous urticaria.

#IFRX InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904

www.stocktitan.net/news/IFRX/infla-rx-annou...

from
Compstatins: the dawn of clinical C3-targeted complement inhibition, by the Lambris lab, UPenn, 2022. (patents to Apellis)
www.sciencedirect.com/science/arti...
Fascinating read and even more fascinating prospects for the effector end, C5aR1 antagonists
#APLS #IFRX

"With several drug candidates targeting pathway-specific initiation (e.g., anti-C1s, anti-MASP2), amplification (e.g., FD and FB inhibitors) and effector functions (e.g., C5aR1 antagonists) in late-stage development, we finally enter a new era in complement-modulating therapies"
#IFRX #APLS

The Pleiotropic Effect of Complement C5a-C5aR1 Pathway in Diseases: From Immune Regulation to Targeted Therapy
www.mdpi.com/1422-0067/26...
Excellent review by Xu, even though the focus on large potential indications, cancer and RA, ignores the breakthrough in smaller short-term opportunities #IFRX

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #AVXL 54% OTM
2. #CLSK 43% OTM
3. #VFF 43% OTM
4. #IFRX 41% OTM
5. #GLXY 40% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#AVXL, #CLSK, #VFF, #IFRX, #GLXY

#OptionFlow #OptionsTrading #Trading

Leading Indicators, Monday November 10, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Mon Nov 10th - #WTBA #UVSP #SLRC #RRBI #PAHC #NRC #NBBK #MATD #LAND #KATS #IFRX #GAIN #FFIC #ELDN #DERM #CABA #BEAT #VSTS #AROW #VSTS #UVE #SMHI #PDS #ORN #MATV #LB #KBDC #GOOS #FSLY #EFXT - More: crystalequityresearch.com/leading-indi... - #smallcap

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #VFF 43% OTM
2. #IFRX 41% OTM
3. #GLXY 40% OTM
4. #NVDA 31% OTM
5. #RDDT 28% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#VFF, #IFRX, #GLXY, #RDDT, #COGT

#OptionFlow #OptionsTrading #Trading

📢 Stocks Trending NOW: #MNDY #PLUG #GLTO #PGY #BYND #IFRX #COGT #B #IMTE #TSN

InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) InflaRx (Nasdaq: IFRX) reported positive topline Phase 2a results for oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) on Nov 10, 2025. Data from 29 HS and 30 CSU patients showed rapid reductions in lesion counts and symptoms over 4 weeks with durable effects at Week 8.Key 4-week signals: HiSCR50 28% (all doses), HiSCR50 Week 8 44% (n=25); AN change −5.1 (all doses); dT100 29%; NRS30 pain response 66%; CSU UAS7 change −10.4 (all doses) and −15.4 in severe CSU (60 mg). No serious adverse events reported. Company targets Phase 2b initiation in HS in 2026 and continues partner discussions.

#IFRX InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)

www.stocktitan.net/news/IFRX/infla-rx-repor...

InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria InflaRx N.V. (Nasdaq: IFRX), a

#IFRX InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria

www.stocktitan.net/news/IFRX/infla-rx-to-an...

InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference InflaRx (Nasdaq: IFRX) will participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA from November 10–12, 2025. The company will appear in a fireside chat on November 11 at 2:30 PM ET and will hold one-on-one investor meetings the same day. A live stream and replay link for the fireside chat will be provided.InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics that target the complement system, developing vilobelimab (intravenous anti-C5a antibody) and INF904 (oral C5a receptor inhibitor). The company has offices in Jena and Munich, Germany, and Ann Arbor, MI.

#IFRX InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference

www.stocktitan.net/news/IFRX/infla-rx-annou...

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #IFRX 104% OTM
2. #BHVN 101% OTM
3. #AVXL 81% OTM
4. #CRCL 80% OTM
5. #BULL 73% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#IFRX, #BHVN, #CRCL, #BULL, #NKLR

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! Weekly Top Unu

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #IFRX 96% OTM
2. #RZLV 67% OTM
3. #LRMR 61% OTM
4. #TSLA 53% OTM
5. #UPST 53% OTM

#OptionFlow #OptionsTrading #Trading

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#IFRX, #RZLV, #BLSH, #SMR, #RR

#OptionFlow #OptionsTrading #Trading

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #IFRX 96% OTM
2. #RZLV 67% OTM
3. #BLSH 65% OTM
4. #UPST 62% OTM
5. #RGTI 56% OTM

#OptionFlow #OptionsTrading #Trading

Biotech Innovator InflaRx to Showcase Anti-Inflammatory Pipeline at Major September Healthcare Conferences Anti-inflammatory biotech InflaRx (IFRX) to present at Cantor Global Healthcare Conference on Sept 4 and H.C. Wainwright Conference on Sept 9, showcasing C5a inhibitor pipeline.

#IFRX InflaRx Announces Participation in September Investor Conferences

www.stocktitan.net/news/IFRX/infla-rx-annou...

InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update InflaRx (NASDAQ:IFRX) reported Q2 2025 financial results and provided key updates on its pipeline. The company's cash position stands at €53.7 million, with runway extending into 2027. Key developments include anticipated INF904 Phase 2a data in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected by early November 2025. Financial highlights show a net loss of €23.0 million (€0.35 per share) for H1 2025. The company's partner Staidson BioPharmaceuticals reported favorable Phase 1/2 results for BDB-001 in ANCA-associated vasculitis, planning to advance to Phase 3. The previously announced Phase 3 pyoderma gangrenosum trial was stopped due to futility, with full data analysis expected later this year. Additionally, enrollment began in the BARDA-funded JUST BREATHE Phase 2 platform trial investigating vilobelimab for acute respiratory distress syndrome (ARDS). The company maintains EU approval for GOHIBIC (vilobelimab) in SARS-CoV-2-induced ARDS and is pursuing commercial partnerships.

#IFRX InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/IFRX/infla-rx-repor...

InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement InflaRx (NASDAQ: IFRX), a biopharmaceutical company focused on anti-inflammatory therapeutics, has received a Nasdaq deficiency notice on July 11, 2025, for failing to maintain the minimum bid price requirement of $1.00 per share for the last 30 consecutive business days.The company has been granted an initial 180-day period until January 7, 2026, to regain compliance. If unsuccessful, InflaRx may consider transferring from Nasdaq Global Select Market to Nasdaq Capital Market, which could provide an additional 180 days until July 6, 2026, subject to meeting other listing requirements.InflaRx develops anti-C5a and anti-C5a receptor technologies, including vilobelimab, an intravenous antibody, and INF904, an oral small molecule inhibitor.

#IFRX InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

www.stocktitan.net/news/IFRX/infla-rx-annou...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping down in trading, Wed May 28th - #SYNX #OGEN #REVB #ELPW #BSLK #SAMG #PLAB #IFRX #CXDO #ANTX #VATE #GWH #CBAN - More: crystalequityresearch.com/SmCpStr/ - #smallcap

InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum InflaRx (IFRX) announced that the Independent Data Monitoring Committee has recommended stopping the Phase 3 trial of vilobelimab for pyoderma gangrenosum (PG) due to futility. The decision was based on data from the first 30 patients, with no unexpected adverse events reported. In response, InflaRx will discontinue vilobelimab development for PG and redirect resources to INF904, their oral C5aR inhibitor. Phase 2a data readouts for INF904 in chronic spontaneous urticaria and hidradenitis suppurativa are expected this summer. The company is considering additional cost savings to extend its cash runway. GOHIBIC (vilobelimab) remains available in the US under Emergency Use Authorization for COVID-19 treatment and has received EU marketing authorization under exceptional circumstances for SARS-CoV-2-induced ARDS patients.

#IFRX InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum

www.stocktitan.net/news/IFRX/infla-rx-annou...

InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update InflaRx (IFRX) reported Q1 2025 financial results and key business updates. The company maintains a strong financial position with €65.7 million in cash and equivalents as of March 31, 2025, providing runway into 2027. Key upcoming catalysts include an interim analysis for vilobelimab's Phase 3 trial in pyoderma gangrenosum (PG) expected in May-June 2025, and topline Phase 2a data for INF904 in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) expected in summer 2025. The company recently completed successful toxicology studies for INF904 and received EU marketing authorization for GOHIBIC (vilobelimab) for SARS-CoV-2-induced ARDS. Q1 2025 resulted in a net loss of €8.3 million (€0.13 per share), improved from €9.7 million loss in Q1 2024. In February 2025, InflaRx raised €28.7 million through a public offering.

#IFRX InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/IFRX/infla-rx-repor...

InflaRx 2024 Earnings Reveal Strong Cash Position and Major EU Drug Win InflaRx secures EU approval for GOHIBIC, raises €28.7M, extending runway to 2027. Phase 3 trial advances with key interim data expected. Strong cash position supports pipeline expansion.

#IFRX InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

www.stocktitan.net/news/IFRX/infla-rx-repor...